Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC)

Early Phase 1TerminatedNCT04968951

Ari M Grinspan4 enrolled

Overview

The researchers intend to prospectively study the safety, clinical efficacy and microbial outcomes in patients with recently diagnosed UC with FMT capsule therapy derived from pre-defined donors. Donors will be specifically screened for Fusobacterium and Sutterella species as well as for global diversity. It is unknown if treatment with antibiotics before FMT improves the engraftment and/or efficacy of FMT in UC, therefore the researchers plan to randomize subjects to receive pre-treatment with antibiotics or not before FMT therapy. The research team enroll patients from The Susan and Leonard Feinstein IBD Center and our established early diagnosis clinic at Mount Sinai Hospital (MSH).

This is an open-label two arm pilot study to measure the safety, microbiological and clinical impacts of FMT in patients with ulcerative colitis. The researchers will prospectively enroll 16 UC patients (up to 20 subjects accounting for subjects dropping out) with moderate-severe disease from one tertiary care referral center. The overall objective of the study is to collect robust clinical data and create a tissue repository including blood, stool and biopsies to understand the safety, efficacy and microbial changes FMT has on UC patients. The central hypothesis is that pre-defined oral capsule administered FMT is safe and effective for the treatment of UC. Objectives: To determine the tolerability, feasibility, and safety of using fecal microbiota transplantation orally as an induction agent for patients with ulcerative colitis. To determine whether fecal microbiota transplantation (FMT) delivered via oral capsules can induce clinical remission in patients with mild to moderate ulcerative colitis. Assess whether pretreatment with antibiotics improves engraftment and efficacy of FMT in UC. To characterize the impact of orally administered FMT on the microbiota of patients with ulcerative colitis, particularly those changes associated with response or lack of response. Study Outcomes: Clinical remission at Week 8, defined as: Steroid-free clinical remission (Total Mayo less 2) and Endoscopic remission (Mayo endoscopic subscore 0 or 1)

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Interventions

MetronidazoleDRUG

Antibiotic treatment - 250 mg every 6 hrs for 5 days

PlaceboDRUG

Placebo treatment

VancomycinDRUG

Antibiotic treatment - 125 mg every 6 hrs for 5 days

Fecal Microbiota TransplantationBIOLOGICAL

Encapsulated biologically active human fecal material (donor stool) is provided in capsule form. The fecal material is homogenized with sterile saline, then pelleted and re-suspended in sterile saline/40% glycerol. Participants will receive 15 FMT capsules per day for 3 consecutive days. Capsule are to be swallowed under direct supervision.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

* Adults aged 18 to 75 with UC, with initial diagnosis of UC \>3 months prior to time of study enrollment visit * Partial Mayo score of 4-10 with endoscopic subscore ≥2 on flexible sigmoidoscopy * Permissible UC medications include oral or rectal administered mesalamines * Corticosteroids must be discontinued at least 4 weeks before enrollment * Documented negative C. difficile and GI PCR for enteric pathogens (BioFire) testing before commencement of fecal microbiota transplantation * Previous documentation of ulcerative colitis based on colonoscopy/flexible sigmoidoscopy with compatible histology

Outcomes

Primary Outcomes

Proportion of participants with an adverse

Safety as measured by proportion of participants with an adverse event through week 8

Time frame: 8 Weeks

Proportion of participants with a severe adverse

Safety as measured by proportion of participants with a severe adverse event through week 8

Time frame: 8 Weeks

Secondary Outcomes

Number of patients requiring escalation of medical therapies

Number of patients requiring escalation of medical therapies based on clinical relapse. Clinical relapse is defined by requiring additional medical therapy.

Time frame: 8 weeks

Proportion of patients that achieve Mayo score 0 or 1

Proportion of patients with initial Mayo 2/3 disease at flexible sigmoidoscopy that achieve endoscopic improvement (Mayo score 0 or 1). The Mayo Score is a composite of subscores (each rated 0-3) from four categories, including stool frequency, rectal bleeding, findings of flexible proctosigmoidoscopy or colonoscopy, and physician's global assessment, with a total score ranging from 0-12, with higher score indicating worse health outcomes.

Time frame: 8 weeks

Number of patients with endoscopic remission

Number of patients with endoscopic remission as defined by a Mayo score of 0

Time frame: 8 weeks

Change in Nancy score

Change in histological score assessed by the Nancy score. The Nancy score includes 3 histologic items that define 5 grades of activity: absence of significant histologic disease, chronic inflammatory infiltrate with no acute inflammatory infiltrate, mildly active disease, moderately active disease, and severely active disease. The Nancy index is defined by a 5-level classification ranging from grade 0 (absence of significant histological disease activity) to grade 4 (severely active disease). higher score indicating worse health outcomes.

Time frame: 8 weeks

Fecal calprotectin level

Mean change fecal calprotectin levels